XNAS · Laboratory Analytical Instruments · S&P 500
$7.00
-$0.01 (-0.09%) today
Open $7.01 High $7.49 Low $6.00 Vol 20K Avg $6.96
Find similar stocks by technical condition — S&P 500 universe
| Symbol | Company Name | Exchange | Currency | Category |
|---|---|---|---|---|
| NEWP | New Pacific Metals Corp. | XASE | USD | - |
| IAG | IAMGold Corporation | XNYS | USD | - |
| BHST | BioHarvest Sciences Inc. Common Stock | XNAS | USD | - |
| BLDP | Ballard Power Systems Inc. | XNAS | USD | - |
| VFS | VinFast Auto Ltd. Ordinary Shares | XNAS | USD | - |
| CHY | Calamos Convertible and High Income Fund | XNAS | USD | - |
| AEC | Anfield Energy Inc. Common Shares | XNAS | USD | - |
| GCDT | Green Circle Decarbonize Technology Limited | XASE | USD | - |
| OXLC | Oxford Lane Capital Corp. | XNAS | USD | - |
| DTSS | Datasea Intelligent Technology Ltd. Class A Ordinary Shares | XNAS | USD | - |
52-week price range
Price is 16.7% above its 52-week low and 84.3% below its 52-week high. Trading in the lower half of its annual range — closer to the floor than the ceiling.
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.